Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.02.2024 | Case report

Cabozantinib/Nivolumab

Cerebral haemorrhage

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sato Y, et al. Contemplation of the Effect of Nivolumab Plus Cabosantinib Therapy on Cerebral Hemorrhage in Patients with Brain Metastasis of Renal Cell Carcinoma: A Case Report. Case Reports in Oncology 16 : 1573-1578, Dec 2023. Available from: URL: https://dx.doi.org/10.1159/000533785 Sato Y, et al. Contemplation of the Effect of Nivolumab Plus Cabosantinib Therapy on Cerebral Hemorrhage in Patients with Brain Metastasis of Renal Cell Carcinoma: A Case Report. Case Reports in Oncology 16 : 1573-1578, Dec 2023. Available from: URL: https://dx.doi.org/10.1159/000533785
Metadaten
Titel
Cabozantinib/Nivolumab
Cerebral haemorrhage
Publikationsdatum
01.02.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53511-6

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Paclitaxel

Case report

Tofacitinib